Camrelizumab - Jiangsu Hengrui Medicine

Drug Profile

Camrelizumab - Jiangsu Hengrui Medicine

Alternative Names: HR-301210; INCSHR1210; SHR-1210

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Hepatocellular carcinoma
  • Phase II Hodgkin's disease; Liver cancer; Solid tumours
  • Phase I/II Biliary cancer
  • Phase I Breast cancer; Malignant melanoma; Nasopharyngeal cancer

Most Recent Events

  • 12 Dec 2017 Jiangsu HengRui Medicine plans a phase II trial for T-cell lymphoma (extranodal NK/T-cell lymphoma) (Recurrent, Second-line therapy or greater) in China , (NCT03363555), in December 2017
  • 08 Dec 2017 Jiangsu HengRui Medicine and Peking University People's Hospital plans a phase II trial for Osteosarcoma (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, In adolescents, In the elderly, In adults) in China in June 2018 (NCT03359018)
  • 06 Nov 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (ChiCTR-OIC-17013249)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top